恩典生命科技(02112)发布中期业绩，股东应占溢利21.1万美元

Core Viewpoint - Grace Life Sciences (02112) reported a significant improvement in its mid-year performance for 2025, showcasing a strong revenue growth and a turnaround in profitability [1] Financial Performance - Revenue reached $8.417 million, representing a year-on-year increase of 41% [1] - The profit attributable to the parent company was $0.211 million, a substantial recovery from a loss of $8.966 million in the same period last year [1] - Basic earnings per share were reported at $0.0001 [1] Sales Growth Drivers - The increase in sales revenue was attributed to the expansion of sales channels for plant stem cells and an increase in the number of customers [1]